ICT Receives FDA Clearance of IND Application to Initiate a Phase 1 Clinical Trial for GCC19CART
ROCKVILLE, Md., Sept. 01, 2021 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a Maryland based clinical stage biotechnology company developing the CoupledCAR® platform of chimeric antigen receptor (CAR) T-cell therapies..